Symbols / IRWD $3.25 -3.71%
IRWD Chart
About
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 529.12M |
| Enterprise Value | 931.85M | Income | 24.02M | Sales | 296.15M |
| Book/sh | -1.61 | Cash/sh | 1.32 | Dividend Yield | — |
| Payout | 0.00% | Employees | 100 | IPO | — |
| P/E | 21.63 | Forward P/E | 2.23 | PEG | — |
| P/S | 1.79 | P/B | -2.02 | P/C | — |
| EV/EBITDA | 7.72 | EV/Sales | 3.15 | Quick Ratio | 1.08 |
| Current Ratio | 1.13 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.15 | EPS next Y | 1.46 | EPS Growth | — |
| Revenue Growth | -47.30% | Earnings | 2026-05-07 | ROA | 19.85% |
| ROE | — | ROIC | — | Gross Margin | 67.88% |
| Oper. Margin | 13.73% | Profit Margin | 8.11% | Shs Outstand | 163.06M |
| Shs Float | 119.18M | Short Float | 11.98% | Short Ratio | 4.17 |
| Short Interest | — | 52W High | 5.78 | 52W Low | 0.53 |
| Beta | 0.19 | Avg Volume | 4.45M | Volume | 9.57M |
| Target Price | $6.10 | Recom | None | Prev Close | $3.37 |
| Price | $3.25 | Change | -3.71% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.10
Mean price target
2. Current target
$3.25
Latest analyst target
3. DCF / Fair value
$12.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.25
Low
$3.70
High
$10.00
Mean
$6.10
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | Citizens | Market Outperform → Market Outperform | $10 |
| 2026-01-05 | main | Wells Fargo | Equal-Weight → Equal-Weight | $5 |
| 2026-01-05 | up | Citizens | Market Perform → Market Outperform | $8 |
| 2025-11-11 | main | Wells Fargo | Equal-Weight → Equal-Weight | $3 |
| 2025-04-15 | down | Wells Fargo | Overweight → Equal-Weight | $1 |
| 2025-04-15 | down | Jefferies | Buy → Hold | $1 |
| 2025-04-14 | main | Leerink Partners | Market Perform → Market Perform | $1 |
| 2025-01-30 | main | JMP Securities | Market Outperform → Market Outperform | $14 |
| 2025-01-22 | main | Craig-Hallum | Buy → Buy | $8 |
| 2024-09-09 | init | Leerink Partners | — → Market Perform | $5 |
| 2024-08-09 | main | Wells Fargo | Overweight → Overweight | $12 |
| 2024-08-09 | main | Craig-Hallum | Buy → Buy | $10 |
| 2024-05-10 | main | Craig-Hallum | Buy → Buy | $14 |
| 2024-03-01 | main | Wells Fargo | Overweight → Overweight | $14 |
| 2024-02-16 | main | Piper Sandler | Overweight → Overweight | $21 |
| 2024-01-17 | init | Craig-Hallum | — → Buy | $21 |
| 2023-12-14 | init | Wells Fargo | — → Overweight | $20 |
| 2023-09-28 | init | JMP Securities | — → Market Outperform | $22 |
| 2023-05-23 | main | Piper Sandler | Overweight → Overweight | $19 |
| 2022-08-16 | main | Wells Fargo | — → Equal-Weight | $13 |
- Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Strong Trading Volume - Should You Buy? - MarketBeat ue, 17 Mar 2026 18
- IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView hu, 12 Mar 2026 16
- Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award - Stock Titan hu, 12 Mar 2026 20
- IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - Zacks Investment Research hu, 12 Mar 2026 15
- Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term - Yahoo Finance ue, 14 Oct 2025 07
- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Up 15.8% in February - MarketBeat ue, 17 Mar 2026 15
- Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st ue, 06 Jan 2026 08
- Ironwood Pharma Maintains Revolving Credit Facility to 2028 - The Globe and Mail hu, 12 Mar 2026 11
- IRWD rises 307% in 6 months: Is this an indication to buy the stock? - MSN Fri, 13 Mar 2026 20
- IRWD or PBYI: Which Small-Cap Biotech Stock Offers a Superior Investment Opportunity? - Bitget hu, 12 Mar 2026 02
- Ironwood Pharmaceuticals Stock (IRWD) Opinions on 2026 Financial Guidance - Quiver Quantitative Fri, 02 Jan 2026 08
- Ironwood Pharma to stream Citizens Life Sciences fireside chat March 11 - Stock Titan Wed, 04 Mar 2026 08
- IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks - Yahoo Finance hu, 26 Feb 2026 08
- Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail hu, 12 Mar 2026 13
- Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating - MarketBeat Wed, 07 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 163934 | — | — | Stock Award(Grant) at price 0.00 per share. | SILVER RONALD | Officer | — | 2026-03-10 00:00:00 | D |
| 1 | 136612 | — | — | Stock Award(Grant) at price 0.00 per share. | MINARDO JOHN | Officer | — | 2026-03-10 00:00:00 | D |
| 2 | 136612 | — | — | Stock Award(Grant) at price 0.00 per share. | MARTINI GREGORY S. | Chief Financial Officer | — | 2026-03-10 00:00:00 | D |
| 3 | 136612 | — | — | Stock Award(Grant) at price 0.00 per share. | GASKINS TAMMI L | Officer | — | 2026-03-10 00:00:00 | D |
| 4 | 136612 | — | — | Stock Award(Grant) at price 0.00 per share. | SHETZLINE MICHAEL | Officer | — | 2026-03-10 00:00:00 | D |
| 5 | 409836 | — | — | Stock Award(Grant) at price 0.00 per share. | MCCOURT THOMAS A | Chief Executive Officer | — | 2026-03-10 00:00:00 | D |
| 6 | 32582 | 121586 | — | Sale at price 3.66 - 3.81 per share. | SHETZLINE MICHAEL | Officer | — | 2026-02-24 00:00:00 | D |
| 7 | 24173 | 90206 | — | Sale at price 3.66 - 3.81 per share. | SILVER RONALD | Officer | — | 2026-02-24 00:00:00 | D |
| 8 | 36492 | 136177 | — | Sale at price 3.66 - 3.81 per share. | MINARDO JOHN | Officer | — | 2026-02-24 00:00:00 | D |
| 9 | 21944 | 81888 | — | Sale at price 3.66 - 3.81 per share. | MARTINI GREGORY S. | Chief Financial Officer | — | 2026-02-24 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -4.25M | -544.53K | -233.89M | 55.78K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.31 |
| NormalizedEBITDA | 124.91M | 102.84M | 188.88M | 261.26M |
| TotalUnusualItems | -20.26M | -2.59M | -1.11B | 182.00K |
| TotalUnusualItemsExcludingGoodwill | -20.26M | -2.59M | -1.11B | 182.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 24.02M | 880.00K | -1.00B | 175.06M |
| ReconciledDepreciation | 1.88M | 2.01M | 1.57M | 1.42M |
| ReconciledCostOfRevenue | 0.00 | 0.00 | ||
| EBITDA | 104.65M | 100.24M | -924.87M | 261.44M |
| EBIT | 102.77M | 98.23M | -926.44M | 260.02M |
| NetInterestIncome | -28.67M | -28.57M | -2.66M | 1.90M |
| InterestExpense | 32.75M | 33.03M | 21.63M | 7.60M |
| InterestIncome | 4.08M | 4.47M | 18.97M | 9.50M |
| NormalizedIncome | 40.02M | 2.93M | -122.38M | 174.94M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 24.02M | 880.00K | -1.00B | 175.06M |
| TotalExpenses | 177.39M | 255.69M | 274.40M | 160.26M |
| TotalOperatingIncomeAsReported | 98.50M | 93.12M | -945.43M | 250.34M |
| DilutedAverageShares | 162.98M | 160.08M | 155.44M | 186.31M |
| BasicAverageShares | 161.84M | 159.08M | 155.44M | 154.37M |
| DilutedEPS | 0.15 | 0.01 | -6.45 | 0.96 |
| BasicEPS | 0.15 | 0.01 | -6.45 | 1.13 |
| DilutedNIAvailtoComStockholders | 24.02M | 880.00K | -1.00B | 179.51M |
| AverageDilutionEarnings | 0.00 | 0.00 | 4.45M | 0.00 |
| NetIncomeCommonStockholders | 24.02M | 880.00K | -1.00B | 175.06M |
| NetIncome | 24.02M | 880.00K | -1.00B | 175.06M |
| MinorityInterests | 0.00 | 29.32M | 0.00 | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | 24.02M | 880.00K | -1.03B | 175.06M |
| NetIncomeDiscontinuousOperations | 0.00 | |||
| NetIncomeContinuousOperations | 24.02M | 880.00K | -1.03B | 175.06M |
| TaxProvision | 46.01M | 64.32M | 83.49M | 77.36M |
| PretaxIncome | 70.03M | 65.20M | -948.07M | 252.42M |
| OtherIncomeExpense | -20.06M | -1.95M | -1.11B | 182.00K |
| OtherNonOperatingIncomeExpenses | 193.00K | 640.00K | ||
| SpecialIncomeCharges | -20.26M | -2.59M | -1.11B | 0.00 |
| OtherSpecialCharges | 1.10B | |||
| RestructuringAndMergernAcquisition | 20.26M | 2.59M | 18.32M | 0.00 |
| GainOnSaleOfSecurity | 19.00K | 182.00K | -1.18M | |
| NetNonOperatingInterestIncomeExpense | -28.67M | -28.57M | -2.66M | 1.90M |
| InterestExpenseNonOperating | 32.75M | 33.03M | 21.63M | 7.60M |
| InterestIncomeNonOperating | 4.08M | 4.47M | 18.97M | 9.50M |
| OperatingIncome | 118.76M | 95.72M | 168.34M | 250.34M |
| OperatingExpense | 177.39M | 255.69M | 274.40M | 160.26M |
| ResearchAndDevelopment | 95.14M | 111.42M | 116.08M | 44.27M |
| SellingGeneralAndAdministration | 82.26M | 144.27M | 158.31M | 115.99M |
| GrossProfit | 410.60M | 413.75M | ||
| CostOfRevenue | 0.00 | 0.00 | ||
| TotalRevenue | 296.15M | 351.41M | 442.74M | 410.60M |
| OperatingRevenue | 296.15M | 351.41M | 442.74M | 410.60M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 163.06M | 160.21M | 156.35M | 154.03M |
| ShareIssued | 163.06M | 160.21M | 156.35M | 154.03M |
| NetDebt | 369.22M | 495.43M | 605.72M | |
| TotalDebt | 597.80M | 599.48M | 715.54M | 415.92M |
| TangibleBookValue | -263.88M | -304.19M | -349.98M | 652.38M |
| InvestedCapital | 322.85M | 282.65M | 351.57M | 1.05B |
| WorkingCapital | 31.96M | 143.52M | -42.81M | 755.10M |
| NetTangibleAssets | -263.88M | -304.19M | -349.98M | 652.38M |
| CapitalLeaseObligations | 13.12M | 15.49M | 17.67M | 19.66M |
| CommonStockEquity | -261.83M | -301.33M | -346.30M | 652.38M |
| TotalCapitalization | 123.17M | 282.65M | 152.01M | 1.05B |
| TotalEquityGrossMinorityInterest | -261.83M | -301.33M | -346.30M | 652.38M |
| MinorityInterest | 0.00 | 0.00 | ||
| StockholdersEquity | -261.83M | -301.33M | -346.30M | 652.38M |
| GainsLossesNotAffectingRetainedEarnings | -1.06M | 923.00K | -3.03M | 0.00 |
| OtherEquityAdjustments | -1.06M | 923.00K | -3.03M | |
| RetainedEarnings | -1.67B | -1.70B | -1.70B | -696.38M |
| AdditionalPaidInCapital | 1.41B | 1.40B | 1.36B | 1.35B |
| CapitalStock | 163.00K | 160.00K | 156.00K | 154.00K |
| CommonStock | 163.00K | 160.00K | 156.00K | 154.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 658.74M | 652.24M | 817.37M | 448.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 416.52M | 613.40M | 541.27M | 422.62M |
| OtherNonCurrentLiabilities | 21.65M | 17.11M | 28.41M | 9.77M |
| LongTermDebtAndCapitalLeaseObligation | 394.87M | 596.29M | 512.85M | 412.85M |
| LongTermCapitalLeaseObligation | 9.87M | 12.30M | 14.54M | 16.60M |
| LongTermDebt | 385.00M | 583.99M | 498.31M | 396.25M |
| CurrentLiabilities | 242.22M | 38.85M | 276.10M | 25.52M |
| OtherCurrentLiabilities | 9.41M | 4.42M | 6.20M | 3.61M |
| CurrentDeferredLiabilities | 1.11M | 2.03M | 2.62M | |
| CurrentDeferredRevenue | 1.11M | 2.03M | 2.62M | |
| CurrentDebtAndCapitalLeaseObligation | 202.93M | 3.19M | 202.69M | 3.06M |
| CurrentCapitalLeaseObligation | 3.25M | 3.19M | 3.13M | 3.06M |
| CurrentDebt | 199.68M | 199.56M | 116.86M | |
| OtherCurrentBorrowings | 199.68M | 199.56M | 116.86M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.59M | 14.55M | 19.94M | 12.27M |
| PayablesAndAccruedExpenses | 17.18M | 14.66M | 44.66M | 6.58M |
| CurrentAccruedExpenses | 13.36M | 12.01M | 35.59M | 5.45M |
| InterestPayable | 4.44M | 4.77M | 5.95M | 188.00K |
| Payables | 3.83M | 2.65M | 9.07M | 1.14M |
| TotalTaxPayable | 927.00K | 521.00K | 1.24M | 656.00K |
| AccountsPayable | 2.90M | 2.13M | 7.83M | 483.00K |
| TotalAssets | 396.90M | 350.91M | 471.07M | 1.10B |
| TotalNonCurrentAssets | 122.72M | 168.54M | 237.78M | 319.89M |
| OtherNonCurrentAssets | 4.50M | 5.92M | 3.61M | 1.33M |
| NonCurrentDeferredAssets | 103.43M | 144.23M | 212.32M | 283.66M |
| NonCurrentDeferredTaxesAssets | 103.43M | 144.23M | 212.32M | 283.66M |
| NonCurrentAccountsReceivable | 14.59M | 24.00M | ||
| GoodwillAndOtherIntangibleAssets | 2.04M | 2.86M | 3.68M | 0.00 |
| OtherIntangibleAssets | 2.04M | 2.86M | 3.68M | |
| NetPPE | 12.75M | 15.52M | 18.17M | 20.31M |
| AccumulatedDepreciation | -8.01M | -8.37M | -8.89M | -10.76M |
| GrossPPE | 20.75M | 23.89M | 27.06M | 31.07M |
| Leases | 7.44M | 7.41M | 7.41M | 7.41M |
| OtherProperties | 9.34M | 11.03M | 13.91M | 15.35M |
| MachineryFurnitureEquipment | 3.97M | 5.45M | 5.74M | 8.32M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 274.18M | 182.37M | 233.29M | 780.63M |
| OtherCurrentAssets | 11.98M | 11.92M | 12.01M | 7.71M |
| HedgingAssetsCurrent | 0.00 | 1.11M | ||
| RestrictedCash | 0.00 | 1.25M | 1.25M | |
| PrepaidAssets | 8.69M | |||
| Receivables | 46.74M | 81.89M | 129.12M | 115.46M |
| AccountsReceivable | 46.74M | 81.89M | 129.12M | 115.46M |
| CashCashEquivalentsAndShortTermInvestments | 215.46M | 88.56M | 92.15M | 656.20M |
| CashAndCashEquivalents | 215.46M | 88.56M | 92.15M | 656.20M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 127.01M | 103.41M | 183.15M | 273.63M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -126.39M | -24.13M |
| RepaymentOfDebt | 0.00 | -265.00M | -100.00M | -120.70M |
| IssuanceOfDebt | 0.00 | 150.00M | 400.00M | 0.00 |
| CapitalExpenditure | -34.00K | -142.00K | -273.00K | -136.00K |
| InterestPaidSupplementalData | 30.33M | 32.56M | 13.55M | 5.75M |
| IncomeTaxPaidSupplementalData | 3.54M | 8.41M | 9.95M | 4.62M |
| EndCashPosition | 215.46M | 88.56M | 92.15M | 657.94M |
| BeginningCashPosition | 88.56M | 92.15M | 657.94M | 621.86M |
| EffectOfExchangeRateChanges | -329.00K | -32.00K | -53.00K | 0.00 |
| ChangesInCash | 127.23M | -3.56M | -565.73M | 36.07M |
| FinancingCashFlow | 216.00K | -106.97M | 277.16M | -237.55M |
| CashFlowFromContinuingFinancingActivities | 216.00K | -106.97M | 277.16M | -237.55M |
| NetOtherFinancingCharges | -2.98M | -29.20M | ||
| ProceedsFromStockOptionExercised | 216.00K | 11.01M | 6.36M | 9.54M |
| NetCommonStockIssuance | 0.00 | 0.00 | -126.39M | -24.13M |
| CommonStockPayments | 0.00 | 0.00 | -126.39M | -24.13M |
| NetIssuancePaymentsOfDebt | 0.00 | -115.00M | 300.00M | -120.70M |
| NetLongTermDebtIssuance | 0.00 | -115.00M | 300.00M | -120.70M |
| LongTermDebtPayments | 0.00 | -265.00M | -100.00M | -120.70M |
| LongTermDebtIssuance | 0.00 | 150.00M | 400.00M | 0.00 |
| InvestingCashFlow | -34.00K | -142.00K | -1.03B | -136.00K |
| CashFromDiscontinuedInvestingActivities | 0.00 | |||
| CashFlowFromContinuingInvestingActivities | -34.00K | -142.00K | -1.03B | -136.00K |
| NetBusinessPurchaseAndSale | 0.00 | -1.03B | 0.00 | 0.00 |
| PurchaseOfBusiness | 0.00 | -1.03B | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -34.00K | -142.00K | -273.00K | -136.00K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -34.00K | -142.00K | -273.00K | -136.00K |
| OperatingCashFlow | 127.04M | 103.55M | 183.43M | 273.76M |
| CashFromDiscontinuedOperatingActivities | 0.00 | |||
| CashFlowFromContinuingOperatingActivities | 127.04M | 103.55M | 183.43M | 273.76M |
| ChangeInWorkingCapital | 41.34M | 739.00K | 11.28M | 2.82M |
| ChangeInOtherCurrentLiabilities | 1.59M | -12.43M | -1.49M | 8.88M |
| ChangeInOtherCurrentAssets | 2.13M | 704.00K | 1.12M | 1.48M |
| ChangeInPayablesAndAccruedExpense | 2.10M | -34.86M | 6.50M | -18.75M |
| ChangeInAccruedExpense | -4.11M | -14.65M | -5.88M | -10.64M |
| ChangeInPayable | 6.20M | -20.21M | 12.38M | -8.12M |
| ChangeInAccountPayable | 6.20M | -20.21M | 12.38M | -8.12M |
| ChangeInPrepaidAssets | 367.00K | 89.00K | 4.22M | 3.22M |
| ChangeInInventory | 0.00 | 0.00 | ||
| ChangeInReceivables | 35.15M | 47.24M | 924.00K | 7.99M |
| ChangesInAccountReceivables | 35.15M | 47.24M | 924.00K | 7.99M |
| OtherNonCashItems | 1.67M | 1.90M | 1.10B | 1.85M |
| StockBasedCompensation | 17.25M | 29.85M | 32.01M | 27.05M |
| DeferredTax | 40.80M | 68.09M | 72.64M | 65.74M |
| DeferredIncomeTax | 40.80M | 68.09M | 72.64M | 65.74M |
| DepreciationAmortizationDepletion | 1.88M | 2.01M | 1.57M | 1.42M |
| DepreciationAndAmortization | 1.88M | 2.01M | 1.57M | 1.42M |
| AmortizationCashFlow | 400.00K | |||
| AmortizationOfIntangibles | 400.00K | |||
| Depreciation | 1.20M | 1.42M | 1.50M | |
| OperatingGainsLosses | 89.00K | 75.00K | -19.00K | -180.00K |
| GainLossOnInvestmentSecurities | -19.00K | -182.00K | 1.18M | |
| GainLossOnSaleOfPPE | 89.00K | 75.00K | 0.00 | 2.00K |
| NetIncomeFromContinuingOperations | 24.02M | 880.00K | -1.03B | 175.06M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IRWD
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|